PHILADELPHIA– (BUSINESS WIRE) – PCI Pharma Services (“PCI” of “het bedrijf”), een toonaangevende leverancier van farmaceutische en biofarmaceutische wereldwijde supply chain-oplossingen, kondigde vandaag de afronding aan van de eerder aangekondigde overname die Kohlberg & Company, LLC ( “Kohlberg”) een meerderheidsbelang in het bedrijf. Mubadala Investment Company en Partners Group (handelend namens haar klanten) zullen minderheidsbelangen hebben in de Vennootschap.
Deze mijlpaal is een belangrijke stap voor PCI, aangezien Kohlberg en Mubadala zullen samenwerken met het managementteam van PCI, geleid door CEO Salim Haffar, om het transformatietraject van het bedrijf voort te zetten. Het team zal op organische en anorganische wijze specifieke capaciteiten en geografische gebieden toevoegen om de klantervaring van PCI te verbeteren en zijn klanten in staat te stellen levensveranderende biofarmaceutische therapieën op de markt te brengen. Gebruikmakend van de wereldwijde groeitrends op het gebied van biologische geneesmiddelen en gespecialiseerde medicamenteuze therapieën, omvatten toekomstige mogelijkheden onder meer steriele afvulafwerking van injectables, uitbreiding van hoge potentie en gespecialiseerde productie, en verdere geografische uitbreiding naar Azië en Europa.
PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala
PHILADELPHIA–(BUSINESS WIRE)– PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today announced the closing of the previously announced acquisition that gives Kohlberg & Company, LLC (“Kohlberg”) a majority stake in the company. Mubadala Investment Company and Partners Group (acting on behalf of its clients) will have minority shares in the Company.
This milestone is a key step for PCI, as Kohlberg and Mubadala will be partnering with PCI’s management team, led by CEO Salim Haffar, to continue the Company’s transformation journey. The team will be adding specific capabilities and geographies organically and inorganically to improve PCI’s client experience and enable its clients to bring life-changing biopharmaceutical therapies to market. Leveraging the global growth trends in biologics and specialized drug therapies, future capabilities include sterile fill finish of injectables, expanding high potency and specialized manufacturing, and further geographic expansion into Asia and greater Europe.
Kohlberg is a leading private equity firm headquartered in Mount Kisco, N.Y., with over 30 years of successful experience partnering with management and companies like PCI Pharma Services. Mubadala Investment Company (“Mubadala”) is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for its shareholder, the government of Abu Dhabi.
About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com.
About Kohlberg & Company, LLC
Kohlberg & Company, LLC (“Kohlberg”) is a leading private equity firm headquartered in Mount Kisco, New York. Since its inception in 1987, Kohlberg has organized nine private equity funds, through which it has raised over $10 billion of committed equity capital. Over its 33-year history, Kohlberg has completed 82 platform investments and approximately 200 add-on acquisitions, with an aggregate transaction value in excess of $25 billion. For more information about Kohlberg & Company, please visit www.kohlberg.com.
About Mubadala Investment Company
Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi.
Mubadala’s $232 billion portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates.
Headquartered in Abu Dhabi, Mubadala has offices in London, Rio de Janeiro, Moscow, New York, San Francisco and Beijing.
For more information about Mubadala Investment Company, please visit www.mubadala.com
About Partners Group
Partners Group is a leading global private markets investment manager. Since 1996, the firm has invested over USD 135 billion in private equity, private real estate, private debt and private infrastructure on behalf of its clients globally. Partners Group is a committed, responsible investor and aims to create broad stakeholder impact through its active ownership and development of growing businesses, attractive real estate and essential infrastructure. With over USD 96 billion in assets under management as of 30 June 2020, Partners Group serves a broad range of institutional investors, sovereign wealth funds, family offices and private individuals globally. The firm employs more than 1,500 diverse professionals across 20 offices worldwide and has regional headquarters in Baar-Zug, Switzerland; Denver, USA; and Singapore. It has been listed on the SIX Swiss Exchange since 2006 (symbol: PGHN). For more information about Partners Group, please visit www.partnersgroup.com
Jefferies LLC served as lead financial advisor to PCI and Morgan Stanley & Co LLC served as co-advisor.
Centerview Partners LLC served as financial advisor to the Kohlberg-Mubadala consortium.
Bailey Watroba, WE Communications
email@example.com / +1 617-234-4110